drugset / Trial / NCT01232023

Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent

NCT01232023

Phase 1 Unknown 12 enrolled Asan Medical Center
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

This study is designed to evaluate the pharmacokinetic and pharmacodynamic characteristics of indobufen in healthy subjects.

Timeline

Start
2010-01
Primary completion
2010-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Indobufen Small molecule 100 mg Oral
Subject Indobufen Small molecule 200 mg Oral
Subject Indobufen Small molecule 400 mg Oral
Subject Indobufen Small molecule 800 mg Oral

Indications

No indication recorded.